Zydus Lifesciences Limited has informed the Exchange about Investor Presentation
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences reported strong Q4 FY25 results with total revenues up 18% YoY to Rs. 65,279 mn and full-year revenues growing 18.9% to Rs. 232,415 mn. All four key businesses—India formulations (+11% Q4 YoY), Consumer Wellness (+17.1% Q4 YoY on 13% volume growth), US Formulations (+24.1% Q4 YoY, $363 mn), and International Markets (+11.8% Q4 YoY)—posted healthy growth. EBITDA margin expanded by 310 bps to 32.6%, with EBITDA up 30% YoY. Net cash surged to Rs. 48,836 mn from Rs. 8,561 mn a year ago. The company disclosed a major foray into MedTech via an agreement to acquire a majority stake in France-based Amplitude Surgical SA, along with new licensing deals (BEIZRAY with Zhuhai Beihai Biotech and an oncology 505(b)(2) product with Synthon BV). R&D spend was 7.4% of revenues, supporting 27 ANDA filings and 24 approvals in FY25.
Strong all-round performance with broad-based growth and margin expansion signals healthy operational momentum; the Amplitude Surgical acquisition marks a strategic entry into MedTech that could reshape the company's growth narrative, potentially supporting a positive re-rating for shareholders.